14:50~16:10
Saturday 17 October
The next wave of diabetes technology
Unboxing the next wave of diabetes technology and therapeutics
Chair(s) Sunghwan SuhSungkyunkwan University, Korea · Jee Hee YooChung-Ang University, Korea
1
Jee Hee Yoo
Chung-Ang University, Korea
Diabetes and MASLD: shared mechanisms and therapeutic targets
2
Rimei Nishimura
Jikei University, Japan
Top-line phase 2 results of DD01, a dual GLP-1/Glucagon agonist: rapid improvements in liver and metabolic parameters in patients with MASLD/MASH
3
Sun Joon Moon
Sungkyunkwan University, Korea
Intestinal IL-22 signaling improves glucose homeostasis in obesity
SESSION OVERVIEW
Diabetes technology was once regarded as largely confined to type 1 diabetes, but its role is now expanding across the diabetes spectrum, with CGM increasingly recognized as a tool that can aid management from diagnosis to any therapeutic stage. This session highlights the evolving use of diabetes technology in intermediate hyperglycemia (Prediabetes), type 2 diabetes, tech-naïve older adults, and pregnancy, and examines how automated insulin delivery in type 2 diabetes is advancing beyond meal-unannounced approaches toward fully closed-loop, “set-and-forget” systems. Together, these talks will provide a timely overview of the next wave of diabetes technology and its expanding role across the continuum of diabetes care.